Literature DB >> 25275117

Differential contribution of adeno-associated virus type 2 Rep protein expression and nucleic acid elements to inhibition of adenoviral replication in cis and in trans.

Stefan Weger1, Eva Hammer2, Regine Heilbronn2.   

Abstract

UNLABELLED: The helper-dependent adeno-associated virus type 2 (AAV-2) exhibits complex interactions with its helper adenovirus. Whereas AAV-2 is dependent on adenoviral functions for productive replication, it conversely inhibits adenoviral replication, both when its genome is present in trans after coinfection with both viruses and when it is present in cis, as in the production of recombinant adenovirus (rAd)/AAV-2 hybrid vectors. The notion that AAV-mediated inhibition of adenoviral replication is due predominantly to the expression of the AAV-2 Rep proteins was recently challenged by successful Rep78 expression in a rAd5 vector through recoding of the Rep open reading frame (ORF). We closely analyzed the relative contributions of AAV-2 nucleic acid elements and Rep protein expression to the inhibition of adenoviral replication in both of the above scenarios. When present in cis, a sequence element in the 3' part of the rep gene, comprising only the AAV-2 p40 promoter and the AAV-2 intron sequence, which we termed the RIS-Ad, completely blocks adenoviral replication. p5/p19 promoter-driven Rep protein expression, on the other hand, only weakly inhibits rAd/AAV-2 vector propagation, and by inactivation of the RIS-Ad, it is feasible to generate first-generation rAd vectors expressing functional Rep proteins. The RIS-Ad plays no role in the inhibition of adenoviral replication in trans in a model closely mimicking AAV-2-Ad coinfection. In this case, expression of the Rep proteins is required, as well as the presence of an amplifiable inverted terminal repeat (ITR)-containing template. Thus, very different AAV-2 elements and mechanisms are involved in inhibition of adenoviral replication during rAd/AAV-2 vector propagation and after Ad-AAV coinfection. IMPORTANCE: This is the first study to systematically compare the contributions of AAV-2 protein expression and AAV-2 nucleic acid elements to the inhibition of adenoviral replication in rAd/AAV-2 hybrid vector generation and in AAV-2-adenovirus coinfection. This study shows that the two inhibitory processes are very different with regard to AAV-2 functions and the mechanisms involved. Whereas inhibition of rAd/AAV-2 hybrid vector propagation mostly involves a 3' nucleic acid element in the rep gene, inhibition of an adenoviral genome in trans requires the Rep proteins and the AAV ITRs. These findings have important implications both for a basic understanding of the AAV replication cycle and for generation of rAd/AAV-2 hybrid vectors expressing the nonstructural and structural proteins of AAV-2.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25275117      PMCID: PMC4249140          DOI: 10.1128/JVI.02350-14

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  33 in total

1.  PKA/PrKX activity is a modulator of AAV/adenovirus interaction.

Authors:  Giovanni Di Pasquale; John A Chiorini
Journal:  EMBO J       Date:  2003-04-01       Impact factor: 11.598

2.  DNA helicase-mediated packaging of adeno-associated virus type 2 genomes into preformed capsids.

Authors:  J A King; R Dubielzig; D Grimm; J A Kleinschmidt
Journal:  EMBO J       Date:  2001-06-15       Impact factor: 11.598

3.  Studies on the relationship between adeno-associated virus type I (AAV-1) and adenoviruses. I. Replication of AAV-1 in certain cell cultures and its effect on helper adenovirus.

Authors:  B C Casto; R W Atchison; W M Hammon
Journal:  Virology       Date:  1967-05       Impact factor: 3.616

4.  A helper-dependent capsid-modified adenovirus vector expressing adeno-associated virus rep78 mediates site-specific integration of a 27-kilobase transgene cassette.

Authors:  Hongjie Wang; André Lieber
Journal:  J Virol       Date:  2006-09-20       Impact factor: 5.103

5.  Herpes simplex virus type 1 amplicon vector-mediated gene transfer to muscle.

Authors:  Yaming Wang; Santwana Mukherjee; Cornel Fraefel; Xandra O Breakefield; Paul D Allen
Journal:  Hum Gene Ther       Date:  2002-01-20       Impact factor: 5.695

6.  Site-specific integration of functional transgenes into the human genome by adeno/AAV hybrid vectors.

Authors:  Alessandra Recchia; Laura Perani; Daniela Sartori; Clelia Olgiati; Fulvio Mavilio
Journal:  Mol Ther       Date:  2004-10       Impact factor: 11.454

7.  Herpes simplex virus type 1/adeno-associated virus hybrid vectors mediate site-specific integration at the adeno-associated virus preintegration site, AAVS1, on human chromosome 19.

Authors:  Thomas Heister; Irma Heid; Mathias Ackermann; Cornel Fraefel
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

8.  An adenoviral expression system for AAV rep78 using homologous recombination.

Authors:  Cheryl A Carlson; Dmitry M Shayakhmetov; André Lieber
Journal:  Mol Ther       Date:  2002-07       Impact factor: 11.454

9.  Studies on the relationship between adeno-associated virus type 1 (AAV-1) and adenoviruses. II. Inhibition of adenovirus plaques by AAV; its nature and specificity.

Authors:  B C Casto; J A Armstrong; R W Atchison; W M Hammon
Journal:  Virology       Date:  1967-11       Impact factor: 3.616

10.  Herpes simplex virus types 1 and 2 completely help adenovirus-associated virus replication.

Authors:  R M Buller; J E Janik; E D Sebring; J A Rose
Journal:  J Virol       Date:  1981-10       Impact factor: 5.103

View more
  2 in total

1.  A Regulatory Element Near the 3' End of the Adeno-Associated Virus rep Gene Inhibits Adenovirus Replication in cis by Means of p40 Promoter-Associated Short Transcripts.

Authors:  Stefan Weger; Eva Hammer; Melanie Gonsior; Catrin Stutika; Regine Heilbronn
Journal:  J Virol       Date:  2016-03-28       Impact factor: 5.103

Review 2.  AAV-mediated gene therapy: Advancing cardiovascular disease treatment.

Authors:  Huili Zhang; Qi Zhan; Biao Huang; Yigang Wang; Xiaoyan Wang
Journal:  Front Cardiovasc Med       Date:  2022-08-19
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.